Literature DB >> 6367799

Histological, epidemiological and clinical aspects of centroblastic-centrocytic lymphomas subdivided according to the "working formulation".

W M Molenaar, H Bartels, J Koudstaal.   

Abstract

A group of 424 lymphomas diagnosed as centroblastic-centrocytic lymphomas at the Lymph Node Registry in Kiel was subdivided into small (S), mixed (M) and large (L) cell groups, according to the "working formulation" proposed in a National Cancer Institute sponsored study. Histological epidemiological and clinical parameters were studied. It was found that in group S a follicular growth pattern was most frequent and in group L a follicular and diffuse growth, while group M took an intermediate position. No statistically significant differences were found in respect to epidemiological factors or overall survival. However, in the first 6 years after the diagnosis the survival in group S was better than in group M, but thereafter a reversal occurred. Group L appeared to have the worst survival throughout. Growth pattern and sclerosis were found to be of limited influence on survival within the cytological groups.

Entities:  

Mesh:

Year:  1984        PMID: 6367799      PMCID: PMC1976751          DOI: 10.1038/bjc.1984.43

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  The natural history of nodular lymphoma.

Authors:  R Qazi; A C Aisenberg; J C Long
Journal:  Cancer       Date:  1976-04       Impact factor: 6.860

Review 2.  A critical analysis of the classifications of non-Hodgkin's lymphomas.

Authors:  B N Nathwani
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

Review 3.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

4.  The coexistence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: significance and clinicopathologic correlation.

Authors:  R A Warnke; H Kim; Z Fuks; R F Dorfman
Journal:  Cancer       Date:  1977-09       Impact factor: 6.860

5.  Immunologic characterization of human malignant lymphomas.

Authors:  R J Lukes; R D Collins
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

6.  Non-Hodgkin's lymphomas: a clinicopathologic study of 293 cases.

Authors:  A S Patchefsky; H S Brodovsky; H Menduke; M Southard; J Brooks; D Nicklas; W S Hoch
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

7.  Morphological studies of 84 untreated patients subjected to laparotomy for the staging of non-Hodgkin's lymphomas.

Authors:  H Kim; R F Dorfman
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

8.  Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.

Authors:  S E Jones; Z Fuks; M Bull; M E Kadin; R F Dorfman; H S Kaplan; S A Rosenberg; H Kim
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

9.  Differences in age and sex distributions among patients with non-Hodgkin's lymphoma.

Authors:  L Elias
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

10.  Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases.

Authors:  R Risdall; R T Hoppe; R Warnke
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

View more
  3 in total

1.  Prognostic importance of DNA flow cytometry in non-Hodgkin's lymphomas.

Authors:  J C Macartney; R S Camplejohn; J Alder; M G Stone; G Powell
Journal:  J Clin Pathol       Date:  1986-05       Impact factor: 3.411

2.  The significance of the number of centroblasts in centroblastic/centrocytic lymphomas. A long term study in a large group of patients.

Authors:  W M Molenaar; H Bartels; J Koudstaal
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

3.  Are follicular large centrocytic and large centroblastic lymphomas one entity?

Authors:  W M Molenaar; J Koudstaal; H Bartels
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.